TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24513113

Group type: COMPARATOR
Intervention: 0F-200 (no fluoride in 200 ml milk)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.5F-100 (1.5 mg fluoride in 100 ml milk)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3F-100 (3 mg fluoride in 100 ml milk)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.5F-200 (1.5 mg fluoride in 200 ml milk)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3F-200 (3 mg fluoride in 200 ml milk)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.5F-200
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fluoride in 100 ml milk
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All fluoridated milk treatments
Number of subjects: 28
Study: 22934395

Group type: EXPERIMENTAL
Intervention: Acupoint injection of autologous blood (2 mL/acupoint, once a week for 4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Motilium (10 mg, 3 times daily for 4 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupoint injection of autologous blood
Number of subjects: 42

Group type: COMPARATOR
Intervention: Motilium
Number of subjects: 42
Study: 19577251

Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 93

Group type: COMPARATOR
Intervention: T-tube insertion
Number of subjects: 93
Study: 17599483

Group type: EXPERIMENTAL
Intervention: Strict glycemic control protocol (insulin administration)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no protocol)
Number of subjects: 300
Study: 15595583

Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia with bupivacaine 0.25%
Number of subjects: 59

Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia with bupivacaine 0.25% and sufentanil 0.001 mg/mL
Number of subjects: 59
Study: 11757212

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (bolus of 70 to 140 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral propafenone (300 to 600 mg)
Number of subjects: 200
Study: 9702292

Group type: EXPERIMENTAL
Intervention: Thyroid carcinoma
Number of subjects: 48

Group type: COMPARATOR
Intervention: Adenomas and surrounding tissue
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carcinomas
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medullary and papillary-follicular carcinoma
Number of subjects: 48

Group type: COMPARATOR
Intervention: Adenomas and surrounding tissues
Number of subjects: 48
Study: 8059021

Group type: EXPERIMENTAL
Intervention: Verapamil (V) 80 mg/8 h per os before surgery and 5 mg/4-6 h slow infusion during the next intra- and postoperative 24-36 h
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 35
Study: 10303912

Group type: EXPERIMENTAL
Intervention: EC/IC bypass grafting
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1377
Study: 6313597

Group type: EXPERIMENTAL
Intervention: High doses of acyclovir (400 to 1200 mg/m2/dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of acyclovir and human alpha interferon (2 to 40 X 10(4) units/kg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 21
Study: 29889248

Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 29133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29133
Study: 28248690

Group type: EXPERIMENTAL
Intervention: Massage treatment (12 twice-weekly 45-min sessions focusing on trigger point release)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham ultrasound sessions
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 62
Study: 26018634

Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 24316711

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All NSAIDs (Diclofenac, Naproxen, Etodolac)
Number of subjects: 42
Study: 21646442

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 51
Study: 20809213

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 17908625

Group type: EXPERIMENTAL
Intervention: Brief chemotherapy and involved-field radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief chemotherapy alone
Number of subjects: 0
Study: 16296963

Group type: EXPERIMENTAL
Intervention: Alcohol/chlorhexidine hand hygiene solution (ACHRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11937123

Group type: EXPERIMENTAL
Intervention: Acupuncture (performed 25 minutes before and after embryo transfer)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (embryo transfer without any supportive therapy)
Number of subjects: 160
Study: 9742523

Group type: EXPERIMENTAL
Intervention: IL-2 7 x 10(5) U, 5-fluorouracil (5-FU) 250 mg/day continuous infusion, mitomycin C (MMC) 4 mg once weekly for unresectable liver metastases
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IL-2 1.4 to 2.1 x 10(6) U, 5-FU 250 mg, MMC 2 to 4 mg weekly for 6 months for resectable liver metastases
Number of subjects: 43
Study: 10150444

Group type: EXPERIMENTAL
Intervention: Continuous and in-depth education on HIV/AIDS
Number of subjects: 548

Group type: COMPARATOR
Intervention: Ordinary traditional education
Number of subjects: 548
Study: 2684552

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 2g IV once daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cefotaxime, 2g IV thrice daily
Number of subjects: 51
Study: 866797

Group type: EXPERIMENTAL
Intervention: 1.0 mg of stilbestrol daily
Number of subjects: 2911

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2911
Study: 31945399

Group type: EXPERIMENTAL
Intervention: Bitter/Placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: Bitter/No-Placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: Water
Number of subjects: 68
Study: 31343440

Group type: EXPERIMENTAL
Intervention: RBP-7000 120 mg (subcutaneous injection, monthly for 52 weeks)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: RBP-7000 120 mg
Number of subjects: 500
Study: 28045670

Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mg I/mL
Number of subjects: 253

Group type: COMPARATOR
Intervention: Iopamidol 370 mg I/mL
Number of subjects: 253
Study: 25762499

Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPP-ACFP
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.05% NaF
Number of subjects: 30
Study: 23349444

Group type: EXPERIMENTAL
Intervention: proADM
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control
Number of subjects: 313
Study: 20937606

Group type: EXPERIMENTAL
Intervention: telcagepant 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: telcagepant 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: zolmitriptan 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: telcagepant 300 mg vs zolmitriptan
Number of subjects: 0
Study: 19536906

Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily (n=101)
Number of subjects: 150

Group type: COMPARATOR
Intervention: High-dose imatinib 800 mg (n=49)
Number of subjects: 150
Study: 17402663

Group type: EXPERIMENTAL
Intervention: Complete-face format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Part-face format
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewpoint transformation
Number of subjects: 0
Study: 15385371

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine 12.5 mg/h (5 mL/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline 5 mL/h via a catheter
Number of subjects: 40
Study: 11414677

Group type: EXPERIMENTAL
Intervention: Dietary energy restriction (750 kcal/d; n = 16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Energy balance (control; n = 8)
Number of subjects: 24
Study: 10052544

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Clarithromycin (250 mg twice daily for 10 days)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 203

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 203
Study: 7998667

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day, administered twice daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) (31.2 mg/day, administered six times per day)
Number of subjects: 56
Study: 3041940

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 31486166

Group type: COMPARATOR
Intervention: High coffee intake (>6 cups daily)
Number of subjects: 114220

Group type: COMPARATOR
Intervention: Higher coffee intake (measured as a continuous variable)
Number of subjects: 114220

Group type: COMPARATOR
Intervention: One cup per day higher coffee intake
Number of subjects: 114220

Group type: COMPARATOR
Intervention: Genetic odds ratio for coffee intake
Number of subjects: 114220
Study: 30767588

Group type: EXPERIMENTAL
Intervention: Cool Kids programme
Number of subjects: 79
Study: 28982836

Group type: EXPERIMENTAL
Intervention: Contact-force irrigated RF ablation
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Short duration cryoballoon ablation (2 min applications)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Standard duration cryoballoon ablation (4 min applications)
Number of subjects: 348
Study: 25497115

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (GRAS dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (absence of sodium benzoate)
Number of subjects: 14
Study: 24481930

Group type: EXPERIMENTAL
Intervention: IT morphine 75 μg with bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IT morphine 150 μg with bupivacaine
Number of subjects: 60
Study: 21515841

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 18608658

Group type: EXPERIMENTAL
Intervention: Sustained Attention to Response Task (SART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard response format
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SART
Number of subjects: 0
Study: 15907359

Group type: EXPERIMENTAL
Intervention: Single Bond (SB, 3M)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dentastic UNO (UNO, Pulpdent)
Number of subjects: 20
Study: 12757449

Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Herbal supplements (23 commonly used)
Number of subjects: 15
Study: 10669688

Group type: COMPARATOR
Intervention: Budesonide 400 microg plus placebo (group 1)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg plus budesonide 200 microg (group 2)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Budesonide 100 microg plus placebo (group 3)
Number of subjects: 213
Study: 9117226

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients aged < 60 years
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients aged >= 60 years
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients with metastatic disease
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prostate cancer patients (both age groups)
Number of subjects: 72
Study: 8418238

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 2 years
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 3532764

Group type: EXPERIMENTAL
Intervention: metaproterenol sulfate by MDI aerosol (130 micrograms) with tube spacer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: metaproterenol sulfate by MDI aerosol (130 micrograms) without tube spacer
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDI plus tube spacer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDI alone
Number of subjects: 16
Study: 29365286

Group type: EXPERIMENTAL
Intervention: Cluster set with 30s rest (CS30)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional set (continuous)
Number of subjects: 12
Study: 27432930

Group type: EXPERIMENTAL
Intervention: 7 weeks interval after RCT
Number of subjects: 265

Group type: COMPARATOR
Intervention: 11 weeks interval after RCT
Number of subjects: 265
Study: 24955611

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 14
Study: 21890844

Group type: EXPERIMENTAL
Intervention: In control: No alcohol! prevention program
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 213
Study: 20225908

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.25 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 0.5 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoprofen 1 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol 15 mg/kg
Number of subjects: 0
Study: 18545191

Group type: EXPERIMENTAL
Intervention: Periodized strength training group (2 sessions per week for 8 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nonperiodized strength training group (same exercises as periodized but no week-to-week variations)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 18
Study: 15910150

Group type: EXPERIMENTAL
Intervention: High self-monitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low self-monitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender neutral jobs
Number of subjects: 0
Study: 12580689

Group type: COMPARATOR
Intervention: D.A.R.E. Plus
Number of subjects: 6237

Group type: COMPARATOR
Intervention: D.A.R.E. only
Number of subjects: 6237

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6237
Study: 10100174

Group type: EXPERIMENTAL
Intervention: Soy protein (single dose, 20 g, 34 mg phytoestrogens)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Soy protein (twice-daily, 20 g, 34 mg phytoestrogens)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Carbohydrate placebo diet
Number of subjects: 51
Study: 8705414

Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast sonography (HyCoSy)
Number of subjects: 66

Group type: COMPARATOR
Intervention: X-ray hysterosalpingography (HSG)
Number of subjects: 66
Study: 1687055

Group type: EXPERIMENTAL
Intervention: Long-acting GnRHa (D-Trp-6-LHRH) microcapsules administered intramuscularly at menstruation
Number of subjects: 114

Group type: COMPARATOR
Intervention: FSH and hMG from day 3 of the cycle without GnRHa pre-treatment
Number of subjects: 114
Study: 6475827

Group type: COMPARATOR
Intervention: Commercial ergogenic supplement (vitamin, mineral, amino acid, and unsaturated fatty acid complex) administered at a dose of three capsules daily for 4 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered for 4 weeks.
Number of subjects: 20
Study: 31188839

Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (SpO2 > 95%)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acclimatization over three days
Number of subjects: 18
Study: 28691893

Group type: EXPERIMENTAL
Intervention: Yellow intraocular lenses (IOLs)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Clear intraocular lenses (IOLs)
Number of subjects: 204
Study: 26050143

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 342

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 342
Study: 25108302

Group type: EXPERIMENTAL
Intervention: Rescue angiography
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Scheduled angiography
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Rescue angiography compared to scheduled angiography
Number of subjects: 1823
Study: 22594565

Group type: EXPERIMENTAL
Intervention: 5mg THC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 10mg THC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: THC (5mg and 10mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: THC (10mg)
Number of subjects: 9
Study: 20862645

Group type: EXPERIMENTAL
Intervention: Pharmacological treatments (modulation of the glutamate system, blocking of serotonin 5-HT-3/2a receptors)
Number of subjects: 0
Study: 18173155

Group type: EXPERIMENTAL
Intervention: Lin'erlai Prescription (LEL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clomid
Number of subjects: 60
Study: 16089148

Group type: EXPERIMENTAL
Intervention: Combined therapy of xiaoke shen'an capsule and conventional western medicine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional western medicine
Number of subjects: 90
Study: 11994935

Group type: EXPERIMENTAL
Intervention: Standardized verbal administration of GDS-SF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-standardized verbal administration of GDS-SF
Number of subjects: 0
Study: 10321295

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7670645

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 883

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 883
Study: 2289388

Group type: EXPERIMENTAL
Intervention: Loestrin
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Ortho 10/11
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Ortho 7/7/7
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 391
Study: 6246005

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination therapy (pivmecillinam and pivampicillin)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pivampicillin
Number of subjects: 39
Study: 30354190

Group type: EXPERIMENTAL
Intervention: SEPA intervention
Number of subjects: 320
Study: 28810061

Group type: EXPERIMENTAL
Intervention: 200 mg IR CTC (equivalent to 88 mg tramadol and 112 mg celecoxib)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100 mg IR tramadol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100 mg celecoxib
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100 mg IR tramadol and 100 mg celecoxib
Number of subjects: 36
Study: 25970619

Group type: EXPERIMENTAL
Intervention: Alberta Infant Motor Scale (AIMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuro‐Sensory Motor Developmental Assessment (NSMDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of AIMS and NSMDA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial assessments using AIMS and NSMDA
Number of subjects: 0
Study: 23969953

Group type: EXPERIMENTAL
Intervention: Experimental F/Sn/chitosan toothpaste (1,400 ppm F(-), 3,500 ppm Sn(2+), 0.5% chitosan)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Experimental NaF toothpaste (1,400 ppm F(-))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 27
Study: 23362725

Group type: EXPERIMENTAL
Intervention: Yogic package (YP) including selected pranayama, cleansing practices, and meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19819790

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg/daily for 30 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Diclofenac 75 mg/daily for 30 days
Number of subjects: 110
Study: 17076614

Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 10
Study: 15535887

Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 14651355

Group type: EXPERIMENTAL
Intervention: Gamma camera uptake method (modified Gates, Gates)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Predicted creatinine clearance method (Cockcroft‐Gault, CG)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Plasma sample clearance method (PSC)
Number of subjects: 133
Study: 9585270

Group type: EXPERIMENTAL
Intervention: Propofol IV infusion titrated to electroencephalographic burst suppression during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol IV infusion
Number of subjects: 30
Study: 7618427

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 160

Group type: COMPARATOR
Intervention: 50 mg pentazocine
Number of subjects: 160
Study: 2729164

Group type: EXPERIMENTAL
Intervention: Pure beta-carotene (12 or 30 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carrots (270 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Broccoli (600 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tomato juice (180 g)
Number of subjects: 30
Study: 665561

Group type: EXPERIMENTAL
Intervention: Egg formula diet with higher protein level (0.6 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Egg formula diet with oat bran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rural Guatemalan diet (0.0875 g protein/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recommended dietary allowances of protein
Number of subjects: 0
Study: 30650565

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 406
Study: 28267945

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation simulator with anatomical modifications
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Novice group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intermediate group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Expert group
Number of subjects: 130